8-K Announcements
6Material company update
Apr 8, 2026·SEC
Material company update
Mar 9, 2026·SEC
Material company update
Mar 6, 2026·SEC
Vicarious Surgical Inc.(RBOT)Earnings, Financials & Key Ratios
RBOT•NYSE
$0.17
Price updated Jul 6, 2026
AboutVicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. It offers Vicarious System, a single-incision surgical robot for ventral hernia repair. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Show more
- Revenue$0
- EBITDA-$50M+23.1%
- Net Income-$50M+20.6%
- EPS (Diluted)-8.45+21.2%
- ROE-177.51%-103.1%
RBOT Price & Volume
Vicarious Surgical Inc. (RBOT) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Threatens Future Operational Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity insolvency risk
Key Thesis Takeaways
- Vicarious Surgical faces a critical liquidity inflection point as it continues to operate without revenue while sustaining quarterly R&D expenditures of $5.0 million.
- The company's reliance on external financing is increasingly precarious, evidenced by a collapse in total assets from $119.9 million in 2023Q4 to $12.6 million in 2026Q1.
- Investors should remain cautious as the firm's inability to achieve commercialization, combined with a debt-to-equity ratio that has surged to 1.91, suggests a high probability of further dilutive capital raises or insolvency.
Verdict Logic
the company's cash runway is critically low at $1.4 million against a quarterly operating loss of $7.5 million, indicating an imminent risk of insolvency.
RBOT Growth Metrics
Vicarious Surgical Inc. (RBOT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM31.65%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM35.41%
Return on Capital
10 Years-73.01%
5 Years-73.91%
3 Years-92.57%
Last Year-134.61%
Peers Comparison
Key metrics vs top competitors for Vicarious Surgical Inc. (RBOT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.17 | $1.1M | -0.02 | — | — | -177.51% | — | |
| $432.83 | $153.29B | 55.00 | 20.51% | 28.15% | 16.89% | — | |
| $179.95 | $9.42B | -64.27 | -27.1% | 4.9% | 9.08% | — | |
| $8.47 | $729.88M | -6.62 | -3.73% | -21.01% | -13.44% | — | |
| $4.56 | $295.82M | -4.90 | 1.59% | -29.44% | -69.5% | — | |
| $313.38 | $120.14B | 37.31 | 11.16% | 13.21% | 15.1% | — |
Compare RBOT vs Peers
Vicarious Surgical Inc. (RBOT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RBOT SEC Filings & Documents
Vicarious Surgical Inc. (RBOT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when RBOT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RBOT Frequently Asked Questions
Vicarious Surgical Inc. (RBOT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is RBOT profitable?
Vicarious Surgical Inc. (RBOT) reported a net loss of $42.1M for fiscal year 2025.
Dividend & Returns
What is RBOT's return on equity?
Vicarious Surgical Inc. (RBOT) has a return on equity (ROE) of -177.5%. Negative ROE indicates the company is unprofitable.
What is Vicarious Surgical Inc.'s free cash flow?
Vicarious Surgical Inc. (RBOT) had negative free cash flow of $39.7M in fiscal year 2025, likely due to heavy capital investments.